Results 71 to 80 of about 8,781 (113)
Some of the next articles are maybe not open access.
Software for Population Pharmacokinetics and Pharmacodynamics
Clinical Pharmacokinetics, 1999Pharmacokinetic-pharmacodynamic modelling is being used increasingly as a tool in drug development because often in phase III clinical trials only sparse data are available for analysis and so a nonlinear mixed effects modelling approach has to be adopted. Specialist data analytical techniques and software are required to analyse such data.
openaire +3 more sources
Clinical Pharmacokinetics, 1986
Good therapeutic practice should always be based on an understanding of pharmacokinetic variability. This ensures that dosage adjustments can be made to accommodate differences in pharmacokinetics due to genetic, environmental, physiological or pathological factors.
B, Whiting, A W, Kelman, J, Grevel
openaire +2 more sources
Good therapeutic practice should always be based on an understanding of pharmacokinetic variability. This ensures that dosage adjustments can be made to accommodate differences in pharmacokinetics due to genetic, environmental, physiological or pathological factors.
B, Whiting, A W, Kelman, J, Grevel
openaire +2 more sources
Nonparametric Methods in Population Pharmacokinetics
The Journal of Clinical Pharmacology, 2020AbstractPopulation pharmacokinetic (PK) modeling is a widely used approach to analyze PK data obtained from groups of individuals, in both industry and academic research. The approach can also be used to analyze pharmacodynamic (PD) data and pooled PK/PD data. There are 2 main families of population PK methods: parametric and nonparametric.
Goutelle, Sylvain +5 more
openaire +3 more sources
Population Pharmacokinetics and Pharmacokinetic-Pharmacodynamic Relationships for Docetaxel
Investigational New Drugs, 2001The population approach has been implemented prospectively in the clinical development of docetaxel (Taxotere). Overall 640 patients were evaluable for the population PK/PD analysis. The PK analysis evidenced significant covariates explaining the inter-patient variability of docetaxel clearance and the PK/PD analysis demonstrated that the variability ...
R, Bruno +4 more
openaire +2 more sources
Annals of Pharmacotherapy, 2004
OBJECTIVE To present a framework within which population pharmacokinetic (PPK) studies should be designed and analyzed and discuss the application of developed PPK models. METHODS Information on PPK was retrieved from a MEDLINE search (1979–December 2003) of the literature and a bibliographic evaluation of review articles and books. This information is
Ene I, Ette +2 more
openaire +2 more sources
OBJECTIVE To present a framework within which population pharmacokinetic (PPK) studies should be designed and analyzed and discuss the application of developed PPK models. METHODS Information on PPK was retrieved from a MEDLINE search (1979–December 2003) of the literature and a bibliographic evaluation of review articles and books. This information is
Ene I, Ette +2 more
openaire +2 more sources
Population Pharmacokinetic Analysis of Bisoprolol
Clinical Pharmacokinetics, 1989The technique of population pharmacokinetic analysis was employed to study the variability in the dose concentration relationship of bisoprolol during its clinical development. The influence of demographic factors on the variability of clearance was investigated in 3 different populations: group I, patients (including an elderly group) with essential ...
J, Grevel, P, Thomas, B, Whiting
openaire +2 more sources
Population Pharmacokinetics of Polymyxin B
Clinical Pharmacology & Therapeutics, 2018Polymyxin B is used as a last treatment resort for multidrug‐resistant Gram‐negative bacterial infections. The objectives of this study were to examine the population pharmacokinetics of polymyxin B and investigate factor(s) influencing pharmacokinetic variability.
Pooja, Manchandani +6 more
openaire +2 more sources
Population pharmacokinetics of cisapride in neonates
European Journal of Clinical Pharmacology, 2002We conducted a population pharmacokinetic analysis of cisapride in neonates to study whether metabolic immaturity in this population may lead to increased concentrations.Cisapride was administered orally in 91 neonates at the dose of 0.2 mg/kg four times a day. Plasma concentrations were measured using a validated HPLC method.
F, Odoul +7 more
openaire +2 more sources
Population pharmacokinetics of etoposide*
Int. Journal of Clinical Pharmacology and Therapeutics, 2002S, Reif +6 more
openaire +2 more sources
Population Pharmacokinetics/Dynamics*
Annual Review of Pharmacology and Toxicology, 1992L B, Sheiner, T M, Ludden
openaire +2 more sources